Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for

Core Viewpoint - Esperion Therapeutics (ESPR) is anticipated to report a year-over-year decline in earnings due to lower revenues, which could significantly affect its stock price depending on the actual results compared to estimates [1][3]. Earnings Expectations - The upcoming earnings report is expected to be released on August 5, with a consensus estimate of a quarterly loss of $0.17 per share, reflecting a year-over-year change of -240% [2][3]. - Revenues are projected to be $66.29 million, down 10.2% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 3.13% lower in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Esperion is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -5.88%, suggesting a bearish outlook from analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the deviation of actual earnings from consensus estimates, but its predictive power is significant mainly for positive readings [8][9]. - Esperion's current Zacks Rank is 3 (Hold), which complicates the prediction of an earnings beat [11]. Historical Performance - In the last reported quarter, Esperion was expected to post a loss of $0.18 per share but actually reported a loss of $0.21, resulting in a surprise of -16.67% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [13]. Industry Comparison - In contrast, BioCryst Pharmaceuticals (BCRX) is expected to post earnings of $0.03 per share for the same quarter, indicating a year-over-year change of +150%, with revenues expected to be $148.85 million, up 36.2% from the previous year [17][18].